This article was originally published in The Gray Sheet
Johnson & Johnson divests its Critikon patient monitoring business to investor group led by Liberty Partners and Critikon management for undisclosed terms. Going private allows Tampa, Florida-based Critikon "to focus on our strength in vital signs monitoring, specifically non-invasive blood pressure detection and blood pressure cuffs, while improving the access to vital information for caregivers," President and CEO Gordie Nye states
You may also be interested in...
GE Medical Systems' purchase of Critikon will allow it to integrate the Tampa, Florida-based firm's DinaMap non-invasive blood pressure software technology with GE's Dash line of patient monitors. The deal is expected to close by year-end.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.